First human study with vasopharm's trauma compound VAS203
11-Jan-2007
The goal of the upcoming phase I study which will start in January 2007 is to demonstrate safety, tolerability and pharmacokinetics of ascending single intravenous administrations of VAS203 in healthy volunteers. Provided that the enrolment of the volunteers proceeds as intended the results of the study are expected in June 2007. The single dose administration study will then be followed by a multiple dose study which is currently planned for July 2007.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.